Neothetics is a clinical-stage specialty pharmaceutical company focused on development and commercialization of therapeutics for the aesthetic market. Our current focus is on localized fat reduction and body contouring. Neothetics’ lead product candidate, LIPO-202, is a injectable treatment for undesirable, localized areas of fat with no downtime and causes no damage below the skin’s surface. Our clinical studies with LIPO-202 do not use local or systemic pain management before or after the procedure.
|Date||Title|| || |
|04/05/17||Neothetics Announces Issuance by USPTO of Eighth Patent Directed to LIPO-202 Lead Clinical Asset|
|SAN DIEGO, April 05, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today announced the issuance of U.S. Patent Number 9,597,531 by the United States Patent and Trademark Office (USPTO). This patent is directed to specific methods of using LIPO-202 and other agents for the reduction of fat accumulation. The ’531 patent is expected to expire no earlier than the fourth quarter of 2031, e... |
|03/29/17||Neothetics to Present at the 16th Annual Needham Healthcare Conference|
|SAN DIEGO, March 29, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today announced that Susan A. Knudson, Neothetics’ Chief Financial Officer, will present at the 16th Annual Needham Healthcare Conference on Wednesday, April 5th at 12:50 PM, Eastern Time at the Westin Grand Central Hotel in New York City.
To receive Neothetics' press releases and other investor information, please go to the Investor Relations page of the company's website at investors.neothetics.com and register fo... |
|03/23/17||Neothetics Provides Business Update and Reports Fourth Quarter 2016 Financial Results|
|SAN DIEGO, March 23, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today provided a business update and reported financial results for the fourth quarter 2016.
“We are encouraged by our progress on our Phase 2 proof of concept trial for LIPO-202 in submental fat reduction and continue to expect top-line data in June 2017,” said Mr. Jeffrey M. Nugent, a member of Neothetics’ Operating Committee and Board of Directors. “We remain excited about the submental fat reduction market and ... |
|03/20/17||Neothetics Announces Last Subject Enrolled in Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat|
|SAN DIEGO, March 20, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today announced completion of subject enrollment for its Phase 2 proof of concept trial, LIPO-202-CL-31, for the reduction of submental subcutaneous fat.
“We are excited to announce the conclusion of enrollment in our first trial with LIPO-202 for the reduction of submental fat. We are encouraged by the strong inve... |
|There are currently no events scheduled.|
Receive E-mail Alerts|
|Sign up to receive e-mail alerts whenever Neothetics, Inc posts new information to the site. Just enter your e-mail address and click Submit.|
Data Provided by Thomson Reuters
Minimum 20 minutes delayed